Volume 16, Issue 1 (January 2018)                   IJRM 2018, 16(1): 9-18 | Back to browse issues page

XML Persian Abstract Print

Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:

Aflatoonian A, Mansoori-Torshizi M, Farid Mojtahedi M, Aflatoonian B, Khalili M A, Amir-Arjmand M H, et al . Fresh versus frozen embryo transfer after gonadotropin-releasing hormone agonist trigger in gonadotropin-releasing hormone antagonist cycles among high responder women: A randomized, multi-center study. IJRM. 2018; 16 (1) :9-18
URL: http://journals.ssu.ac.ir/ijrmnew/article-1-944-en.html
1- Research and Clinical Center for Infertility, Yazd Reproductive Sciences Institute, Shahid Sadoughi University of Medical Sciences, Yazd, Iran.
2- Novin Infertility Center, Mashhad, Iran
3- Department of Obstetrics and Gynecology, Endocrinology and Female Infertility Unit, Roointan Arash Women's Health Research and Educational Hospital, Tehran University of Medical Sciences, Tehran, Iran
4- Stem Cell Biology Research Center, Yazd Reproductive Sciences Institute, Shahid Sadoughi University of Medical Sciences, Yazd, Iran
5- Madar Hospital, Yazd, Iran.
6- Research and Clinical Center for Infertility, Yazd Reproductive Sciences Institute, Shahid Sadoughi University of Medical Sciences, Yazd, Iran
7- Madar Hospital, Yazd, Iran
8- Armaghan Infertility & IVF Clinic, Mashhad, Iran.
9- The Fertility Clinic, Skive Regional Hospital and Faculty of Health, Aarhus University, Aarhus, Denmark , peter.humaidan@midt.rm.dk
Abstract:   (3224 Views)
Background: The use of embryo cryopreservation excludes the possible detrimental effects of ovarian stimulation on the endometrium, and higher reproductive outcomes following this policy have been reported. Moreover, gonadotropin-releasing hormone agonist trigger in gonadotropin-releasing hormone (GnRH) antagonist cycles as a substitute for standard human chorionic gonadotropin trigger, minimizes the risk of ovarian hyperstimulation syndrome (OHSS) in fresh as well as frozen embryo transfer cycles (FET).
Objective: To compare the reproductive outcomes and risk of OHSS in fresh vs frozen embryo transfer in high responder patients, undergoing in vitro fertilization triggered with a bolus of GnRH agonist.
Materials and Methods: In this randomized, multi-centre study, 121 women undergoing FET and 119 women undergoing fresh ET were investigated as regards clinical pregnancy as the primary outcome and the chemical pregnancy, live birth, OHSS development, and perinatal data as secondary outcomes.
Results: There were no significant differences between FET and fresh groups regarding chemical (46.4% vs. 40.2%, p=0.352), clinical (35.8% vs. 38.3%, p=0.699), and ongoing (30.3% vs. 32.7%, p=0.700) pregnancy rates, also live birth (30.3% vs. 29.9%, p=0.953), perinatal outcomes, and OHSS development (35.6% vs. 42.9%, p=0.337). No woman developed severe OHSS and no one required admission to hospital.
Conclusion: Our findings suggest that GnRHa trigger followed by fresh transfer with modified luteal phase support in terms of a small human chorionic gonadotropin bolus is a good strategy to secure good live birth rates and a low risk of clinically relevant OHSS development in in vitro fertilization patients at risk of OHSS.
Full-Text [PDF 477 kb]   (538 Downloads) |   |   Full-Text (HTML)  (182 Views)  
Type of Study: Review Article |

1. Kupka MS, Ferraretti AP, de Mouzon J, Erb K, D'Hooghe T, Castilla JA, et al. Assisted reproductive technology in Europe, 2010: results generated from European registers by ESHREdagger. Hum Reprod 2014; 29: 2099-2113. [DOI:10.1093/humrep/deu175]
2. DiLuigi AJ, Engmann L, Schmidt DW, Maier DB, Nulsen JC, Benadiva CA. Gonadotropin-releasing hormone agonist to induce final oocyte maturation prevents the development of ovarian Fresh versus frozen embryo transfer International Journal of Reproductive BioMedicine Vol. 16. No. 1. pp: 9-18, January 2018 17 hyperstimulation syndrome in high-risk patients and leads to improved clinical outcomes compared with coasting. Fertil Steril 2010; 94: 1111-1114. [DOI:10.1016/j.fertnstert.2009.10.034]
3. Engmann L, DiLuigi A, Schmidt D, Nulsen J, Maier D, Benadiva C. The use of gonadotropin-releasing hormone (GnRH) agonist to induce oocyte maturation after cotreatment with GnRH antagonist in high-risk patients undergoing in vitro fertilization prevents the risk of ovarian hyperstimulation syndrome: a prospective randomized controlled study. Fertil Steril 2008; 89: 84-91. [DOI:10.1016/j.fertnstert.2007.02.002]
4. Engmann L, Siano L, Schmidt D, Nulsen J, Maier D, Benadiva C. GnRH agonist to induce oocyte maturation during IVF in patients at high risk of OHSS. Reprod Biomed Online 2006; 13: 639-644. [DOI:10.1016/S1472-6483(10)60653-0]
5. Griesinger G, Schultz L, Bauer T, Broessner A, Frambach T, Kissler S. Ovarian hyperstimulation syndrome prevention by gonadotropin-releasing hormone agonist triggering of final oocyte maturation in a gonadotropin-releasing hormone antagonist protocol in combination with a "freeze-all" strategy: a prospective multicentric study. Fertil Steril 2011; 95: 2029-2033. [DOI:10.1016/j.fertnstert.2011.01.163]
6. Humaidan P, Alsbjerg B. GnRHa trigger for final oocyte maturation: is HCG trigger history? Reprod Biomed Online 2014; 29: 274-280. [DOI:10.1016/j.rbmo.2014.05.008]
7. Humaidan P, Kol S, Papanikolaou EG; Copenhagen GnRH Agonist Triggering Workshop Group. GnRH agonist for triggering of final oocyte maturation: time for a change of practice? Hum Reprod Update 2011; 17: 510-524. [DOI:10.1093/humupd/dmr008]
8. Humaidan P, Polyzos NP, Alsbjerg B, Erb K, Mikkelsen AL, Elbaek HO, et al. GnRHa trigger and individualized luteal phase hCG support according to ovarian response to stimulation: two prospective randomized controlled multi-centre studies in IVF patients. Hum Reprod 2013; 28: 2511-2521. [DOI:10.1093/humrep/det249]
9. Humaidan P, Westergaard LG, Mikkelsen AL, Fukuda M, Yding Andersen C. Levels of the epidermal growth factor-like peptide amphiregulin in follicular fluid reflect the mode of triggering ovulation: a comparison between gonadotrophin-releasing hormone agonist and urinary human chorionic gonadotrophin. Fertil Steril 2011; 95: 2034-2038. [DOI:10.1016/j.fertnstert.2011.02.013]
10. Leth-Moller K, Hammer Jagd S, Humaidan P. The Luteal Phase after GnRHa Trigger-Understanding An Enigma. Int J Fertil Steril 2014; 8: 227-234.
11. Imbar T, Kol S, Lossos F, Bdolah Y, Hurwitz A, Haimov-Kochman R. Reproductive outcome of fresh or frozen-thawed embryo transfer is similar in high-risk patients for ovarian hyperstimulation syndrome using GnRH agonist for final oocyte maturation and intensive luteal support. Hum Reprod 2012; 27: 753-759. [DOI:10.1093/humrep/der463]
12. Humaidan P. Luteal phase rescue in high-risk OHSS patients by GnRHa triggering in combination with low-dose HCG: a pilot study. Reprod Biomed Online 2009; 18: 630-634. [DOI:10.1016/S1472-6483(10)60006-5]
13. Humaidan P, Bungum L, Bungum M, Yding Andersen C. Rescue of corpus luteum function with peri-ovulatory HCG supplementation in IVF/ICSI GnRH antagonist cycles in which ovulation was triggered with a GnRH agonist: a pilot study. Reprod Biomed Online 2006; 13: 173-178. [DOI:10.1016/S1472-6483(10)60612-8]
14. Humaidan P, Ejdrup Bredkjaer H, Westergaard LG, Yding Andersen C. 1,500 IU human chorionic gonadotropin administered at oocyte retrieval rescues the luteal phase when gonadotropin-releasing hormone agonist is used for ovulation induction: a prospective, randomized, controlled study. Fertil Steril 2010; 93: 847-854. [DOI:10.1016/j.fertnstert.2008.12.042]
15. Davenport MJ, Vollenhoven B, Talmor AJ. Gonadotropin-Releasing Hormone-Agonist Triggering and a Freeze-All Approach: The Final Step in Eliminating Ovarian Hyperstimulation Syndrome? Obstet Gynecol Surv 2017; 72: 296-308. [DOI:10.1097/OGX.0000000000000432]
16. Roque M, Valle M, Kostolias A, Sampaio M, Geber S. Freeze-all cycle in reproductive medicine: current perspectives. JBRA Assist Reprod 2017; 21: 49-53. [DOI:10.5935/1518-0557.20170012]
17. Roque M. Freeze-all policy: is it time for that? J Assist Reprod Genet 2015; 32: 171-176. [DOI:10.1007/s10815-014-0391-0]
18. Aflatoonian A, Karimzadeh Maybodi MA, Aflatoonian N, Tabibnejad N, Amir-Arjmand MH, Soleimani M, et al. Perinatal outcome in fresh versus frozen embryo transfer in ART cycles. Int J Reprod Biomed 2016; 14: 167-172. [DOI:10.29252/ijrm.14.3.167]
19. Fritz MA SL. Clinical Gynecologic Endocrinology and Infertility. 8th Ed. Lipincott Williams & Wilkins; 2011: 1322-1323.
20. Huang CY, Shieh ML, Li HY. The benefit of individualized low-dose hCG support for high responders in GnRHa-triggered IVF/ICSI cycles. J Chin Med Assoc 2016; 79: 387-393. [DOI:10.1016/j.jcma.2016.02.006]
21. Kol S, Humaidan P. GnRH agonist triggering: recent developments. Reprod Biomed Online 2013; 26: 226-230. [DOI:10.1016/j.rbmo.2012.11.002]
22. Datta AK, Eapen A, Birch H, Kurinchi-Selvan A, Lockwood G. Retrospective comparison of GnRH agonist trigger with HCG trigger in GnRH antagonist cycles in anticipated high-responders. Reprod Biomed Online 2014; 29: 552-558. [DOI:10.1016/j.rbmo.2014.08.006]
23. Radesic B, Tremellen K. Oocyte maturation employing a GnRH agonist in combination with low-dose hCG luteal rescue minimizes the severity of ovarian hyperstimulation syndrome while maintaining excellent pregnancy rates. Hum Reprod 2011; 26: 3437-3442. [DOI:10.1093/humrep/der333]
24. Haahr T, Roque M, Esteves SC, Humaidan P. GnRH Agonist Trigger and LH Activity Luteal Phase Support versus hCG Trigger and Conventional Luteal Phase Support in Fresh Embryo Transfer IVF/ICSI Cycles-A Systematic PRISMA Review and Meta-analysis. Front Endocrinol 2017; 8: 116. [DOI:10.3389/fendo.2017.00116]
25. Youssef MA, Van der Veen F, Al-Inany HG, Mochtar MH, Griesinger G, Nagi Mohesen M, et al. Gonadotropin-releasing hormone agonist versus HCG for oocyte triggering in antagonist-assisted reproductive technology. Cochrane Database Syst Rev 2014: CD008046. [DOI:10.1002/14651858.CD008046.pub4]
26. Krishna D, Dhoble S, Praneesh G, Rathore S, Upadhaya A, Rao K. Gonadotropin-releasing hormone agonist trigger is a better alternative than human chorionic gonadotropin in PCOS undergoing IVF cycles for an OHSS Free Clinic: A Randomized control trial. J Hum Reprod Sci 2016; 9: 164-172. [DOI:10.4103/0974-1208.192056]
27. Vlaisavljevic V, Kovacic B, Knez J. Cumulative live birth rate after GnRH agonist trigger and elective cryopreservation of all embryos in high responders. Reprod Biomed Online 2017; 35: 42-48. [DOI:10.1016/j.rbmo.2017.03.017]
28. Borges E Jr., Braga DP, Setti AS, Vingris LS, Figueira RC, Iaconelli A Jr. Strategies for the management of OHSS: Results from freezing-all cycles. JBRA Assist Reprod 2016; 20: 8-12. [DOI:10.5935/1518-0557.20160003]
29. Aflatoonian A, Mansoori Moghaddam F, Mashayekhy M, Mohamadian F. Comparison of early pregnancy and neonatal outcomes after frozen and fresh embryo transfer in ART cycles. J Assist Reprod Genet 2010; 27: 695-700. [DOI:10.1007/s10815-010-9470-z]
30. Belva F, Bonduelle M, Roelants M, Verheyen G, Van Landuyt L. Neonatal health including congenital malformation risk of 1072 children born after vitrified embryo transfer. Hum Reprod 2016; 31: 1610-1620. [DOI:10.1093/humrep/dew103]

Send email to the article author

© 2021 All Rights Reserved | International Journal of Reproductive BioMedicine

Designed & Developed by : Yektaweb